New biomarker data supports NeuroSense’s ALS drug

NeuroSense has shared new biomarker data from the Phase IIb PARADIGM study, showing that its amyotrophic lateral sclerosis (ALS) drug PrimeC (celecoxib and ciprofloxacin) regulated iron levels at 12 months.